Impact of self-financed rotavirus vaccines on hospital stays and costs in Spain after a 3-year introductory period. Redondo-González, O., Tenías-Burillo, J. M., & Ruiz-Gonzalo, J. Epidemiology and Infection, April, 2017. doi abstract bibtex Vaccination has reduced rotavirus hospitalizations by 25% in European regions with low-moderate vaccine availability. We aimed to quantify the reduction in hospital costs after the longest period in which Rotarix® and Rotateq® were simultaneously commercially available in Spain. Cases, length of stay (LOS), and diagnosis-related groups (DRGs) were retrieved from the Minimum Basic Data Set. Healthcare expenditure was estimated through the cost accounting system Gescot®. DRGs were clustered: I, non-bacterial gastroenteritis with complications; II, without complications; III, requiring surgical/other procedures or neonatal cases (highest DRG weights). Comparisons between pre (2003-2005)- and post-vaccine (2007-2009) hospital stays and costs by DRG group were made. Rotaviruses were the most common agents of specific-coded gastroenteritis (N = 1657/5012). LOS and extended LOS of rotaviruses fell significantly in 2007-2009 (β-coefficient = -0·43, 95% confidence intervals (95% CI) -0·68 to -0·17; and odds ratio 0·62, 95% CI 0·50-0·76, respectively). Overall, costs attributable to rotavirus hospitalizations fell approximately €244 per patient (95% CI -365 to -123); the decrease in DRG group III was €2269 per patient (95% CI -4098 to -380). We concluded modest savings in hospital costs, largely attributable to cases with higher DRG weights, and a faster recovery. A universal rotavirus vaccination program deserves being re-evaluated, regarding its potential high impact on both at-risk children and societal costs.
@article{redondo-gonzalez_impact_2017,
title = {Impact of self-financed rotavirus vaccines on hospital stays and costs in {Spain} after a 3-year introductory period},
issn = {1469-4409},
doi = {10.1017/S0950268817000620},
abstract = {Vaccination has reduced rotavirus hospitalizations by 25\% in European regions with low-moderate vaccine availability. We aimed to quantify the reduction in hospital costs after the longest period in which Rotarix® and Rotateq® were simultaneously commercially available in Spain. Cases, length of stay (LOS), and diagnosis-related groups (DRGs) were retrieved from the Minimum Basic Data Set. Healthcare expenditure was estimated through the cost accounting system Gescot®. DRGs were clustered: I, non-bacterial gastroenteritis with complications; II, without complications; III, requiring surgical/other procedures or neonatal cases (highest DRG weights). Comparisons between pre (2003-2005)- and post-vaccine (2007-2009) hospital stays and costs by DRG group were made. Rotaviruses were the most common agents of specific-coded gastroenteritis (N = 1657/5012). LOS and extended LOS of rotaviruses fell significantly in 2007-2009 (β-coefficient = -0·43, 95\% confidence intervals (95\% CI) -0·68 to -0·17; and odds ratio 0·62, 95\% CI 0·50-0·76, respectively). Overall, costs attributable to rotavirus hospitalizations fell approximately €244 per patient (95\% CI -365 to -123); the decrease in DRG group III was €2269 per patient (95\% CI -4098 to -380). We concluded modest savings in hospital costs, largely attributable to cases with higher DRG weights, and a faster recovery. A universal rotavirus vaccination program deserves being re-evaluated, regarding its potential high impact on both at-risk children and societal costs.},
language = {eng},
journal = {Epidemiology and Infection},
author = {Redondo-González, O. and Tenías-Burillo, J. M. and Ruiz-Gonzalo, J.},
month = apr,
year = {2017},
pmid = {28367780},
pages = {1--13},
}
Downloads: 0
{"_id":"ni9DmsE3p5Z9mKcBG","bibbaseid":"redondogonzlez-tenasburillo-ruizgonzalo-impactofselffinancedrotavirusvaccinesonhospitalstaysandcostsinspainaftera3yearintroductoryperiod-2017","author_short":["Redondo-González, O.","Tenías-Burillo, J. M.","Ruiz-Gonzalo, J."],"bibdata":{"bibtype":"article","type":"article","title":"Impact of self-financed rotavirus vaccines on hospital stays and costs in Spain after a 3-year introductory period","issn":"1469-4409","doi":"10.1017/S0950268817000620","abstract":"Vaccination has reduced rotavirus hospitalizations by 25% in European regions with low-moderate vaccine availability. We aimed to quantify the reduction in hospital costs after the longest period in which Rotarix® and Rotateq® were simultaneously commercially available in Spain. Cases, length of stay (LOS), and diagnosis-related groups (DRGs) were retrieved from the Minimum Basic Data Set. Healthcare expenditure was estimated through the cost accounting system Gescot®. DRGs were clustered: I, non-bacterial gastroenteritis with complications; II, without complications; III, requiring surgical/other procedures or neonatal cases (highest DRG weights). Comparisons between pre (2003-2005)- and post-vaccine (2007-2009) hospital stays and costs by DRG group were made. Rotaviruses were the most common agents of specific-coded gastroenteritis (N = 1657/5012). LOS and extended LOS of rotaviruses fell significantly in 2007-2009 (β-coefficient = -0·43, 95% confidence intervals (95% CI) -0·68 to -0·17; and odds ratio 0·62, 95% CI 0·50-0·76, respectively). Overall, costs attributable to rotavirus hospitalizations fell approximately €244 per patient (95% CI -365 to -123); the decrease in DRG group III was €2269 per patient (95% CI -4098 to -380). We concluded modest savings in hospital costs, largely attributable to cases with higher DRG weights, and a faster recovery. A universal rotavirus vaccination program deserves being re-evaluated, regarding its potential high impact on both at-risk children and societal costs.","language":"eng","journal":"Epidemiology and Infection","author":[{"propositions":[],"lastnames":["Redondo-González"],"firstnames":["O."],"suffixes":[]},{"propositions":[],"lastnames":["Tenías-Burillo"],"firstnames":["J.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Ruiz-Gonzalo"],"firstnames":["J."],"suffixes":[]}],"month":"April","year":"2017","pmid":"28367780","pages":"1–13","bibtex":"@article{redondo-gonzalez_impact_2017,\n\ttitle = {Impact of self-financed rotavirus vaccines on hospital stays and costs in {Spain} after a 3-year introductory period},\n\tissn = {1469-4409},\n\tdoi = {10.1017/S0950268817000620},\n\tabstract = {Vaccination has reduced rotavirus hospitalizations by 25\\% in European regions with low-moderate vaccine availability. We aimed to quantify the reduction in hospital costs after the longest period in which Rotarix® and Rotateq® were simultaneously commercially available in Spain. Cases, length of stay (LOS), and diagnosis-related groups (DRGs) were retrieved from the Minimum Basic Data Set. Healthcare expenditure was estimated through the cost accounting system Gescot®. DRGs were clustered: I, non-bacterial gastroenteritis with complications; II, without complications; III, requiring surgical/other procedures or neonatal cases (highest DRG weights). Comparisons between pre (2003-2005)- and post-vaccine (2007-2009) hospital stays and costs by DRG group were made. Rotaviruses were the most common agents of specific-coded gastroenteritis (N = 1657/5012). LOS and extended LOS of rotaviruses fell significantly in 2007-2009 (β-coefficient = -0·43, 95\\% confidence intervals (95\\% CI) -0·68 to -0·17; and odds ratio 0·62, 95\\% CI 0·50-0·76, respectively). Overall, costs attributable to rotavirus hospitalizations fell approximately €244 per patient (95\\% CI -365 to -123); the decrease in DRG group III was €2269 per patient (95\\% CI -4098 to -380). We concluded modest savings in hospital costs, largely attributable to cases with higher DRG weights, and a faster recovery. A universal rotavirus vaccination program deserves being re-evaluated, regarding its potential high impact on both at-risk children and societal costs.},\n\tlanguage = {eng},\n\tjournal = {Epidemiology and Infection},\n\tauthor = {Redondo-González, O. and Tenías-Burillo, J. M. and Ruiz-Gonzalo, J.},\n\tmonth = apr,\n\tyear = {2017},\n\tpmid = {28367780},\n\tpages = {1--13},\n}\n\n","author_short":["Redondo-González, O.","Tenías-Burillo, J. M.","Ruiz-Gonzalo, J."],"key":"redondo-gonzalez_impact_2017","id":"redondo-gonzalez_impact_2017","bibbaseid":"redondogonzlez-tenasburillo-ruizgonzalo-impactofselffinancedrotavirusvaccinesonhospitalstaysandcostsinspainaftera3yearintroductoryperiod-2017","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":[],"search_terms":["impact","self","financed","rotavirus","vaccines","hospital","stays","costs","spain","year","introductory","period","redondo-gonzález","tenías-burillo","ruiz-gonzalo"],"title":"Impact of self-financed rotavirus vaccines on hospital stays and costs in Spain after a 3-year introductory period","year":2017}